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Abstract
Background: Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membrane-
expressed IgE, leading to depletion of IgE-switched and memory B cells. In patients with mild asthma, quilizumab
reduced serum IgE and attenuated the early and late asthmatic reaction following whole lung allergen challenge.
This study evaluated the efficacy and safety of quilizumab in adults with allergic asthma, inadequately controlled
despite high-dose inhaled corticosteroids (ICS) and a second controller.
Methods: Five hundred seventy-eight patients were randomized to monthly or quarterly dosing regimens of
subcutaneous quilizumab or placebo for 36 weeks, with a 48-week safety follow-up. Quilizumab was evaluated for
effects on the rate of asthma exacerbations, lung function, patient symptoms, serum IgE, and pharmacokinetics.
Exploratory analyses were conducted on biomarker subgroups (periostin, blood eosinophils, serum IgE, and exhaled
nitric oxide).
Results: Quilizumab was well tolerated and reduced serum total and allergen-specific IgE by 30–40 %, but had no
impact on asthma exacerbations, lung function, or patient-reported symptom measures. At Week 36, the 300 mg
monthly quilizumab group showed a 19.6 % reduction (p = 0.38) in the asthma exacerbation rate relative to
placebo, but this was neither statistically nor clinically significant. Biomarker subgroups did not reveal meaningful
efficacy benefits following quilizumab treatment.
Conclusions: Quilizumab had an acceptable safety profile and reduced serum IgE. However, targeting the IgE
pathway via depletion of IgE-switched and memory B cells was not sufficient for a clinically meaningful benefit for
adults with allergic asthma uncontrolled by standard therapy.
Trial registration: ClinicalTrials.gov NCT01582503
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Background
Asthma, a chronic inflammatory disorder of the airways,
affects over 300 million people worldwide [1]. Some
patients have persistent symptoms despite the use of
steroids and other therapies. These patients are at the
highest risk for future exacerbations and unscheduled
use of healthcare resources [2].
Asthma is a heterogeneous disorder with distinct
endotypes, the pathogenic cellular and molecular mech-
anisms that drive disease in different patient subgroups
[3–6]. Allergic asthma is a hypersensitivity driven by the
complex interaction of epithelial, dendritic, and type 2
innate lymphoid cells, leading to activation of CD4+ T
helper 2 (Th2) cells in response to allergen exposure [7].
Th2 cells produce interleukin (IL)-4, IL-5, IL-13, and
other cytokines that promote immunoglobulin E (IgE)
class switching of B cells, increased IgE synthesis by
plasma B cells, and recruitment and activation of
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eosinophils and other inflammatory cells. When allergen
cross-links IgE bound to IgE receptors on mast cells and
basophils, cell activation and allergic mediator release
occur, which may lead to mucus production and airway
hyperreactivity [8]. Biomarkers in sputum, bronchoalve-
olar lavage, blood, and bronchial biopsies may indicate a
particular endotype and potentially identify patients with
increased responsiveness to endotype-specific treatments
[5, 9]. For example, elevated levels of serum periostin, an
extracellular matrix protein induced by IL-4 and IL-13
in airway epithelium, identified a subset of asthma pa-
tients who responded better to lebrikizumab, an anti-IL-
13 monoclonal antibody [10]. Similarly, patients with
high levels of exhaled nitric oxide (NO), blood eosinophils,
or serum periostin, had fewer asthma exacerbations fol-
lowing treatment with omalizumab, a neutralizing anti-
IgE antibody, than patients with low biomarker levels [11].
These data suggest that IgE may drive allergic asthma in a
subset of patients.
Quilizumab is a humanized, monoclonal IgG1 that
binds to the M1-prime segment present only on mem-
brane IgE [12], but not on soluble IgE in serum [13–15].
Membrane IgE is expressed on IgE-switched B cells, IgE
memory B cells, and IgE plasmablasts, but not on IgE
plasma cells [16]. In animal studies, anti-M1 prime bound
membrane IgE on IgE-switched B cells and plasmablasts
and depleted them through apoptosis and antibody-
dependent cell-mediated cytotoxicity, leading to fewer IgE
plasma cells and less production of soluble IgE [17].
We previously evaluated the safety, tolerability, and ac-
tivity of quilizumab in Phase Ia (31 healthy volunteers)
[18], Phase Ib (24 allergic rhinitis patients) [19] and
Phase IIa (15 mild asthma patients) [19] studies. In these
studies, quilizumab reduced serum total IgE by approxi-
mately 25 %. These decreases were sustained for at least
6 months after the last dose, in contrast to omalizumab,
which must be administered every 2–4 weeks to main-
tain reduced IgE levels [20]. Quilizumab also abrogated
the increase in challenge-specific IgE in patients with
mild asthma following a whole-lung allergen challenge,
and reduced the early and late asthmatic reactions [19].
Quilizumab may reset the IgE repertoire by targeting IgE
production and provide a more sustained effect with a
lower dose frequency then omalizumab. The primary
purpose of this study was to evaluate the efficacy, safety,
and pharmacokinetics of quilizumab after 36 weeks of
treatment in adults with allergic asthma inadequately
controlled despite high-dose inhaled corticosteroids
(ICS) and a second controller.
Methods
Trial design
The COSTA trial of quilizumab was a Phase II, randomized,
double-blind, placebo-controlled study (including recruiting
sites from 14 countries: Argentina, Belgium, Bulgaria,
Canada, Germany, Hungary, Mexico, New Zealand, Peru,
Poland, Romania, Russia, Ukraine, and the United States)
that enrolled 578 adults with uncontrolled allergic asthma.
Patients were randomly assigned (1:1:1:1) to one of three
dosing regimens of quilizumab or placebo using an inter-
active web response system. Randomization was stratified
based on serum periostin level (<50 ng/mL, ≥50 ng/mL), ex-
acerbation history (number of exacerbations (1, >1) requir-
ing use of systemic corticosteroids in the prior 18 months),
IgE level (≤75 IU/mL, 75–200 IU/mL, >200 IU/mL), and
country. Patients and study site personnel were blinded to
treatment assignments until all follow-up data through
Week 84 were collected and verified.
Quilizumab (Genentech, Inc., South San Francisco,
CA) was delivered subcutaneously at nine monthly inter-
vals at 300 mg per dose (300 mg M), or at three quar-
terly intervals and at Week 4 at 150 or 450 mg per dose
(150 or 450 mg Q). The treatment period ended
36 weeks after randomization and was followed by a 48-
week period to assess the sustained efficacy and safety of
quilizumab (see Additional file 1: Figure S1).
Ethics, consent, and permissions
Quorum Review based in Seattle, WA was the primary
central IRB used by sites in North America, however
multiple other site-specific institutional review boards at
other global sites approved the protocol and patients
gave written, informed consent. The trial was conducted
in full conformance with the International Conference
on Harmonisation E6 guidelines and the Declaration of
Helsinki, or laws and regulations of the country where
the research was conducted, whichever afforded greater
protection to the individual.
Participants
Inclusion criteria
Adult asthma patients, aged 18–75 years, were re-
quired to have: bronchodilator reversibility of either
≥12 % β-agonist reversibility using 4 puffs of a short-
acting β − agonist (SABA) or a PC20 FEV1 methacholine
(provocative concentration of methacholine producing a
20 % fall in FEV1 (forced expiratory volume in 1 s)) of
8 mg/mL or less, within the last 2 years; a pre-
bronchodilator FEV1 at screening of 40–80 % predicted;
daily use of ICS (≥400 μg/day total daily dose of flutica-
sone propionate or equivalent) and a second controller for
a minimum of 3 consecutive months; inadequately-
controlled asthma as documented by a 5-item Asthma
Control Questionnaire (ACQ-5) [21] score ≥1.50 at
screening and randomization, despite compliance with
asthma controller therapy; at least one positive
aeroallergen-specific IgE (≥0.35 kU(A)/L), or a total serum
IgE ≥75 IU/mL; and a history of at least one protocol-
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defined asthma exacerbation in the 18 months prior to
screening. Asthma exacerbations were defined as new or
increased asthma symptoms (wheezing, cough, chest
tightness, shortness of breath, or nighttime awakening
due to symptoms) that led to treatment with systemic cor-
ticosteroids for at least 3 days or to hospitalization.
Exclusion criteria
Patients were excluded from the study if they had an
asthma exacerbation requiring systemic steroids in the
30 days prior to screening, or between screening and
randomization, a >20 % relative change in FEV1 between
screening and randomization, any pre-existing active
lung disease other than asthma, any infections, elevated
IgE levels for reasons other than allergy, or were former
or current smokers.
Outcome measures
The primary efficacy outcome was the annualized rate of
protocol-defined asthma exacerbations from baseline to
Week 36.
Secondary efficacy outcomes included assessments of
lung function using the relative change in pre-
bronchodilator FEV1 from baseline to Weeks 12 and 36
and the change in asthma symptoms from baseline to
Week 36, using total and daytime symptom severity
scores derived from a daily patient diary. The diary was
also used to determine the proportion of patients who
had no nighttime awakenings due to asthma symptoms
and the proportion of patients with fewer than 2 days of
SABA use per week by Week 36.
Exploratory outcome measures included the change in
asthma control from baseline to Week 36, as measured
by the ACQ-5. To assess the change in allergy-related
quality-of-life measures from baseline to Week 36, the
Standardized Asthma Quality of Life Questionnaire
(AQLQ(S)) [22] and the Standardized Rhinoconjunctivi-
tis Quality of Life Questionnaire (RQLQ(S)) [23] were
administered at patient visits throughout the treatment
and follow-up periods. We also evaluated the ability of
biomarkers (serum periostin, blood eosinophils, exhaled
NO, and serum IgE) to predict benefit from quilizumab.
Safety outcomes were assessed throughout the 36-
week treatment and 48-week follow-up periods.
Assessments
The patient daily diary included two sections in addition
to peak flow measurements: 1) a morning section cap-
turing awakenings and rescue medication use at night,
and symptoms on awakening; and 2) an evening section
capturing daytime symptom severity, rescue medication
use, preventive inhaler use, activity impairment during
the day, and nasal symptoms. The modified total asthma
symptom score (mTASS) was generated from a subset of
diary questions adapted from a previous questionnaire
[24], scoring nighttime awakenings (0–3), symptoms on
awakening (0–1), and daytime symptom severity (0–4),
for a total score range of 0–8. For the analyses of symp-
tom scores, rescue medication use, and nighttime awak-
enings, daily scores were averaged over the previous
7 days prior to the time point of interest. Baseline values
were derived from a minimum of 10 days of patient
diary entries during the 14 days prior to the first
treatment.
Pharmacokinetics and immunogenicity
Serum levels of quilizumab for pharmacokinetic assess-
ments were measured using a validated enzyme-linked
immunosorbent assay (ELISA; Genentech, Inc., South
San Francisco, CA). The pharmacokinetic outcomes in-
cluded: serum concentrations prior to dosing at Weeks
0, 4, 12, 24, and 32; serum concentrations at Week 5
and Week 25; maximum observed serum concentrations
(Cmax,obs); time of maximum observed serum concentra-
tion (Tmax, obs); and terminal elimination half-life (t1/2).
Serum anti-therapeutic antibodies (ATAs) were assessed
in samples at Weeks 0, 4, 12, 24, 36, 48, 60, and 84 using
a validated bridging ELISA (Genentech, Inc., South San
Francisco, CA).
Biomarkers
Samples for biomarker assessments were collected
throughout the study. Allergen-specific and total IgE
were measured in serum by ImmunoCAP® Specific IgE
blood tests (ViraCor-IBT Laboratories, Lee’s Summit,
MO). Specific IgE was measured for the following aller-
gens: cat, house dust mite (HDM) Dermatophagoides
farinae, HDM Dermatophagoides pteronyssinus, rag-
weed, aspergillus, timothy grass, bermuda grass, oak,
birch, plantain, and orchard grass. The maximum spe-
cific IgE was defined as the specific IgE with the highest
titer of specific IgEs pre-dose in each patient. Only ob-
served values of IgE levels were analyzed, with no im-
putation performed for missing IgE data. Peripheral
blood eosinophil counts were obtained from standard
complete blood counts. Serum periostin was mea-
sured by immunoassay using the Roche Elecsys plat-
form (Roche Diagnostics Ltd., Rotkreuz, Switzerland).
Fractional exhaled nitric oxide (FeNO) was measured
using a hand-held portable device, NIOX MINO®
(Niox; Morrisville, NC), according to American Thor-
acic Society/European Respiratory Society 2009 guide-
lines [25].
Statistical methods
All patients received at least one dose of study drug
(intention-to-treat, ITT population) and were included
in all safety and efficacy analyses. Demographic and
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baseline characteristics were summarized using descriptive
statistics. The primary endpoint, the annualized exacerba-
tion rate, was calculated by the total number of protocol-
defined exacerbations observed in the group over the
treatment period divided by total patient-weeks at risk
(number of weeks from first study drug administration to
the earliest of Week 36 or study discontinuation) for the
group and multiplied by 52. For patients who discontin-
ued the study prematurely, there was no imputation of
additional exacerbations. The rates of asthma exacerba-
tions were compared between study groups using a Pois-
son regression with overdispersion model, including terms
for periostin status (<50, ≥50 ng/mL), number of prior ex-
acerbations (1, >1), and IgE level (<200, ≥200 IU/mL). For
biomarker subgroup analyses, unadjusted asthma ex-
acerbation rates were calculated. Corresponding two-
sided p-values and 90 % confidence intervals (CI) were
reported.
The relative change in pre-bronchodilator FEV1 from
baseline was calculated as the absolute change in FEV1
(volume in liters) from baseline divided by the FEV1 at
baseline. For secondary and exploratory end points, the
means and standard deviations of all values for relative
change were calculated according to study group at Weeks
12 and 36. The mean relative changes from baseline were
compared between the study groups using the differences
between the means for each group, with the associated
two-sided 90 % CIs. Missing values were imputed using the
last-observation-carried-forward (LOCF) approach, as pre-
specified in the statistical analysis plan. An analysis of co-
variance (ANCOVA) model with factors for baseline level,
periostin status (<50 ng/mL, ≥50 ng/mL), number of prior ex-
acerbations (1, >1), and IgE level (<200 IU/mL, ≥200 IU/mL)
was fit to assess the treatment effect.
Sample size determination
We planned to randomize 560 patients to one of three
dose regimens of quilizumab or placebo in a 1:1:1:1 ratio
(140 patients per group). This sample size provided ap-
proximately 84 % power to detect a 50 % reduction in
average exacerbation rates due to quilizumab, assuming
0.63 exacerbations per patient in the placebo group over a
36-week treatment period, and a significance level of α =
0.10. This sample size also provided approximately 70 %
power to detect a 50 % reduction in average exacerbation
rates in the subgroup of periostin-high patients, assuming
0.69 exacerbations per patient in the placebo group over
the 36-week period, a significance level of 0.15, and 50 %
of patients in each treatment arm to be periostin high.
Results
Patient demographics and study flow
1212 patients were screened for eligibility and 578 adult
asthma patients (18–75 years old) were enrolled (Fig. 1)
from April 2012 to September 2013; the study was com-
pleted in November 2014. There were no major imbal-
ances between treatment groups, but the 300 mg
monthly quilizumab group had a lower mean age
(45 versus 47–48 years) and a lower median IgE level
(190 versus 234–254 IU/mL) compared to the other treat-
ment arms (Table 1). 89 % (384/433) of patients who re-
ceived quilizumab and 91 % (132/145) of patients who
received placebo completed the study treatment. The
sponsor terminated the trial early because of the lack of
efficacy for the primary end-point (asthma exacerbations)
at Week 36, with the median time in the study at
72 weeks.
Safety
Quilizumab was well tolerated, and the number of pa-
tients experiencing at least one adverse event (AE) was
comparable between all treatment groups (Table 2).
Through Week 36, the most frequent AEs across all qui-
lizumab dose groups were worsening of asthma (27 %),
nasopharyngitis (15 %), upper respiratory tract infection
(7 %), bronchitis (5 %), sinusitis (5 %), and injection site
pain (5 %).
The treatment-emergent ATA rate was 1.4 % in both
the 150 mg Q and 300 mg M groups, and 2.1 % in the
450 mg Q group. ATA incidence for all dosing groups
was 1.6 % (7 of 427 quilizumab-dosed patients). There
was no apparent impact of positive ATA results on ei-
ther pharmacokinetic profiles or safety.
Pharmacokinetics
Quilizumab displayed linear pharmacokinetics with a
dose-proportional increase in exposure as shown by in-
creases in Cmax values between the 150 and 450 mg Q
doses at Weeks 5 and 25. (see Additional file 1: Figure S2).
At treatment Weeks 4, 12, and 24, the mean trough
serum concentrations of quilizumab were: (150 mg Q)
5.7 ± 2.3 μg/mL, 2.6 ± 2.0 μg/mL, and 1.3 ± 4.6 μg/mL,
respectively; (450 mg Q) 17.1 ± 7.0 μg/mL, 7.2 ±
3.8 μg/mL, and 2.3 ± 2.2 μg/mL, respectively; and
(300 mg M) 11.6 ± 4.5 μg/mL, 16.7 ± 6.7 μg/mL, and
16.8 ± 7.7 μg/mL, respectively. For the 150 mg Q,
450 mg Q, and 300 mg M doses, the mean Cmax,obs
values were 18 ± 7.8 μg/mL, 51.6 ± 19.5 μg/mL, and
34 ± 12.6 μg/mL, which occurred at Tmax,obs of 36.4 ±
4.3 days, 36.2 ± 3.0 days, and 36.2 ± 3.5 days, respect-
ively, approximately 7 days following the second
doses. Based on non-compartmental analysis, the
mean t1/2 values of quilizumab across the dose groups
ranged from 16.4 to 18.7 days, which suggests that
steady-state was attained by the time the final doses
were administered for both monthly and quarterly
regimens.
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Fig. 1 Study flow chart. I/E, inclusion/exclusion; M, monthly; Q, quarterly














Age (y) 47.9 (13.0) 46.8 (13.3) 47.0 (13.6) 44.8a (12.2) 46.6 (13.1)
Gender (Female) 84 (58 %) 89 (61 %) 98 (68 %) 86 (60 %) 357 (62 %)
Race (White) 122 (84 %) 119 (82 %) 117 (81 %) 114 (80 %) 472 (82 %)
Weight (kg) 82.8 (23.3) 81.4 (18.13) 80.3 (21.4) 81.3 (19.4) 81.4 (20.6)
Previous number of exacerbations
1 90 (62 %) 88 (61 %) 91 (63 %) 89 (62 %) 358 (62 %)
2 30 (21 %) 33 (23 %) 31 (21 %) 28 (20 %) 122 (21 %)
≥3 25 (17 %) 24 (17 %) 23 (16 %) 26 (18 %) 98 (17 %)
FEV1 % predicted 60.8 (11.9) 58.6 (12.2) 61.2 (12.8) 63 (12.7) 60.9 (12.5)
FEV1 % reversibility 19.6 (15.8) 23.3 (20.6) 21.6 (18.8) 23.4 (18.0) 22 (18.4)
IgE (IU/mL) median 234.0 254.0 249.5 190.0a 232.5
Periostin (ng/mL) median 51.0 53.4 52.4 52.1 51.9
FeNO (ppb) 33.4 (32.0) 35.7 (36.26) 33.8 (32.1) 35.2 (32.5) 34.5 (33.2)
Eosinophils (cells/μl) median 210 220 220 240 220
Mean (SD) unless otherwise noted
aThe 300 mg M treatment group had a lower age and IgE level
M monthly, Q quarterly
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Pharmacodynamic biomarkers
Quilizumab gradually reduced mean serum total and
allergen-specific IgE, reaching a 30–40 % reduction at
Week 36 in all three quilizumab cohorts (p < 0.01 com-
pared to placebo; Fig. 2). The largest decreases in total
and allergen-specific IgE were observed at Week 42 in
the 300 mg M treatment cohort. Serum total and
allergen-specific IgE in quilizumab-treated patients grad-
ually increased throughout the safety follow-up period,
but did not return to pre-dose levels by the end of the
study period (Week 84).
Peripheral blood eosinophils and FeNO levels were not
modified following quilizumab treatment (see Additional
file 1: Figure S3).
Asthma exacerbation rates
Quilizumab treatment did not produce a clinically mean-
ingful reduction of the rate of asthma exacerbations over
the 36-week treatment period. In the ITT population, the
reduction in the asthma exacerbation rate relative to pla-
cebo was 19.6 % (90 % CI: −21 to 47; p = 0.38), −11.2 %
(90 % CI: −63 to 24; p = 0.65), and −5.7 % (90%CI: −55 to
28; p = 0.81) in the 300 mg M, 450 mg Q, and 150 mg Q
quilizumab treatment arms, respectively (Fig. 3).
Subgroup analysis by baseline serum periostin (≥50 ng/
ml, <50 ng/ml), blood eosinophils (≥300 cells/μl, <300
cells/μl), FeNO (≥20 ppb, <20 ppb) and serum total IgE
(≥200 IU/mL, <200 IU/mL) demonstrated no consistent
effect of quilizumab on the exacerbation rate across all
doses when compared to the ITT population (Fig. 4).
Lung function
No significant evidence of improved FEV1 at Weeks 12
and 36 was observed in quilizumab-treated patients
compared to placebo (Fig. 5). The highest relative im-
provement compared to placebo occurred in the lowest
dose arm (150 mg Q), but no meaningful improvements
were observed in the higher dose arms (450 mg Q and
300 mg M). Relative changes from baseline in FEV1
compared to placebo were 3.8 % (90 % CI: −1.2 to
8.9, p = 0.21) at Week 12 and 5.6 % (90 % CI: 0.6 to
10.6, p = 0.07) at Week 36 in the 150 mg Q treatment
arm; 2.2 % (90 % CI: −2.8 to 7.2, p = 0.48) at Week
12 and 0.1 % (90 % CI: −5.0 to 5.1, p = 0.98) at Week
36 in the 450 mg Q arm; and 1.1 % (90 % CI: −3.9
to 6.1, p = 0.72) at Week 12 and 0.1 % (90 % CI: −4.9
to 5.2, p = 0.96) at Week 36 in the 300 mg M arm
(Fig. 5; see Additional file 2: Table S1 and Additional
file 3: Table S2).
Analysis of FEV1 in the biomarker subgroups dem-
onstrated no consistent or meaningful improvements
of FEV1 in the quilizumab-treated arms over placebo
(see Additional file 2: Table S1 and Additional file 3:
Table S2).
Patient-reported outcomes
During the 36-week treatment period, no meaningful dif-
ferences were observed between the quilizumab dose
groups compared with the placebo group for the total
mTASS, daytime mTASS, ACQ-5, AQLQ(S), or RQLQ(S)
scores (Table 3).
Treatment with quilizumab failed to increase either
the proportion of patients who used a SABA for fewer
than 2 days in the prior week or the proportion of pa-
tients who did not awaken at night due to asthma symp-
toms for all dosing levels relative to the placebo group at
Week 36 (Table 3).














Any AE 114 (78.6 %) 110 (75.9 %) 108 (74.5 %) 103 (72.0 %) 321 (74.1 %)
Serious AE 12 (8.3 %) 11 (7.6 %) 10 (6.9 %) 16 (11.2 %) 37 (8.5 %)
Grade 3 AE or higher 21 (14.5 %) 28 (19.3 %) 30 (20.7 %) 24 (16.8 %) 82 (18.9 %)
Grade 2 AE or higher 86 (59.3 %) 78 (53.8 %) 80 (55.2 %) 82 (57.3 %) 240 (55.4 %)
Infections and infestations 76 (52.4 %) 73 (50.3 %) 71 (49.0 %) 68 (47.6 %) 212 (49.0 %)
Parasitic infections 0 0 0 1 (0.7 %) 1 (0.2 %)
Serious infections 3 (2.1 %) 3 (2.1 %) 1 (0.7 %) 2 (1.4 %) 6 (1.4 %)
Injection site reactions 12 (8.3 %) 10 (6.9 %) 13 (9.0 %) 7 (4.9 %) 30 (6.9 %)
Serious injection site reactions 0 0 0 0 0
AE leading to treatment withdrawal 1 (0.7 %) 4 (2.8 %) 1 (0.7 %) 1 (0.7 %) 6 (1.4 %)
Malignancies 0 2 (1.4 %) 2 (1.4 %) 0 4 (0.9 %)
Deaths 0 0 0 0 0
AE adverse event, M monthly, Q quarterly
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Discussion
In this study, we evaluated the efficacy and safety of
quilizumab, a monoclonal antibody that targets the
M1-prime segment of membrane IgE, in adult
patients with allergic asthma that was inadequately
controlled with standard therapy. After 36 weeks of
treatment, quilizumab was well tolerated, with a
safety profile consistent with previous clinical studies
[18, 19].
Quilizumab demonstrated clear pharmacological activ-
ity by reducing both serum total and allergen-specific
IgE an average of 30–40 % from baseline in all three
treatment arms, in agreement with our previous work
[18, 19]. However, quilizumab treatment did not show
Fig. 2 Effect of quilizumab on serum total (a-c) and allergen-specific IgE (d-f) from baseline to Week 84. IgE levels were represented as the mean ±
standard error (SE) of the natural logarithm (a, d), the mean ± SE percent change from baseline (b, e), and median percent change from baseline (c, f).
All IgE data analysis was based on observed values. M, monthly; Q, quarterly
Fig. 3 Rate of protocol-defined asthma exacerbations through Week 36 for all patients. M, monthly; Q, quarterly
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consistent and clinically meaningful benefits in reducing
asthma exacerbations or improving lung function, symp-
toms, or quality of life. Subgroup analysis in patients
with elevated serum periostin, blood eosinophils, FeNO,
or serum IgE did not demonstrate a consistent treatment
effect for quilizumab.
It is important to understand that reducing serum IgE
levels is not quilizumab’s proposed mechanism of action.
Quilizumab did not reduce serum IgE as effectively as
omalizumab (89–98 % reduction of median free IgE)
[26], but these two antibodies target the IgE pathway in
distinctly different ways. Quilizumab targets both B-cell
switching to IgE and the new stimulation of IgE memory
B cells and plasmablasts that lead to enhanced IgE pro-
duction, processes that occur locally in the airways of
allergic patients [16]. Quilizumab’s ability to suppress
the challenge-specific increase in serum IgE in our
whole lung allergen challenge study in mild asthmatics
supports this mechanism [19]. We therefore hypothesize
that quilizumab prevents the formation of short-lived
IgE plasma cells in the airway. Long-lived IgE plasma
cells, which lack IgE on the surface, are not targeted by
quilizumab and may be responsible for the remaining
serum IgE detected in our studies [16]. Another source
of IgE not eliminated by quilizumab may be a subpopu-
lation of IgG1 memory B cells that undergo a secondary
switch to IgE when reactivated, and thereby become IgE
memory cells [27].
The current study assessed the relevance of this mech-
anism on exacerbations in patients with inadequately
Fig. 4 Rate of protocol-defined asthma exacerbations through Week 36 for patients stratified by biomarkers (a: periostin; b: blood eosinophils; c:
FeNO; d: serum IgE). Exac, exacerbation; M, monthly; Q, quarterly
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controlled allergic asthma. In the EXTRA study that ex-
amined a similar patient population, omalizumab signifi-
cantly reduced asthma exacerbations by 25 % in the all-
patients group [24], by 53 % in the FeNO-high subgroup,
and by 32 % in the eosinophil-high subgroup, relative to
placebo. In addition, asthma exacerbations were substan-
tially reduced in the periostin-high subgroup (30 %) rela-
tive to placebo [11]. In contrast, in our study,
quilizumab did not show significant clinical benefit in
this population (Fig. 3) or in any subgroup (Fig. 4), pos-
sibly because local IgE production by short-lived IgE
plasma cells is not critical for exacerbations and other
clinical endpoints. For this to be true, we must assume
that: 1) quilizumab depleted all M1-prime-positive B
cells, and 2) the doses in this study were sufficient to de-
plete all M1-prime-positive cells. Despite our extensive
efforts, we have not been able to accurately detect M1-
prime-positive cells in patients with asthma [19], so we
have no direct evidence of depletion. However, all three
quilizumab dose regimens led to a similar reduction in
serum IgE levels, suggesting that quilizumab depleted all
target cells, and indicating that higher doses would not
have provided additional activity. Interestingly, after stop-
ping quilizumab dosing, serum IgE levels gradually in-
creased, indicating that IgE-switching and formation of
short-lived IgE plasma cells may occur continuously in
this patient population, a finding not previously reported.
The allergen-challenge model used in our previous stud-
ies where quilizumab was shown to be effective [19] may
not represent the asthma processes occurring in the patient
population in this study, especially given that alternate
sources of IgE appear to play a more dominant role. How-
ever, the model was key in first demonstrating the effective-
ness of omalizumab in patients with mild asthma, where
omalizumab significantly reduced both the early and late
asthmatic responses following allergen challenge and re-
duced serum IgE almost completely [28, 29]. Although less
effective than omalizumab in a similar population, quilizu-
mab showed reductions of 26 and 36 % in the early and late
asthmatic responses, respectively, and a 25 % reduction in
serum IgE [19]. Allergen-challenge studies are generally ex-
ploratory and are designed to follow biomarkers that trend
with early and late asthmatic responses. They are usually
conducted in patients with mild asthma, which is not the
typical target population for new biologic therapies. At least
one therapy, mepolizumab (anti-IL-5), is effective for redu-
cing asthma exacerbations in patients with eosinophilic
asthma, yet does not appear to affect early/late asthmatic
responses during allergen challenge [30, 31]. It is therefore
crucial that appropriate patient populations and outcome
measures are selected for future trials.
Whether quilizumab could have a clinically meaning-
ful effect in another subgroup of allergic asthma patients
or whether a treatment period beyond 36 weeks
would show efficacy, are questions we are unable to
address with the current study. The type 2 biomarkers,
serum periostin, blood eosinophils, and FeNO, which










Mean change in total asthma symptoms
score (mTASS)
−1.5 0.1, p = 0.58 0.1, p = 0.55 −0.1, p = 0.51
Mean change in daytime asthma symptoms
score (mTASS)
−0.7 0.1, p = 0.55 0, p = 0.70 0, p = 0.69
Mean change in ACQ-5 score −1.2 0, p = 0.86 0, p = 0.83 −0.1, p = 0.52
Mean change in AQLQ(S) score 1.1 −0.1, p = 0.67 0.1, p = 0.73 0.3, p = 0.05
Mean change in RQLQ(S) score −0.6 0, p = 0.96 −0.1, p = 0.35 −0.3, p = 0.04
Proportion of patients at Week 36 with no
nighttime awakenings in the previous week
0.43 −0.07, p = 0.21 −0.02, p = 0.69 0, p = 0.97
Proportion of patients at Week 36 with ≤2
days of rescue medication use in the previous week
0.42 0.01, p = 0.88 0.01, p = 0.86 0.06, p = 0.33
ITT intention-to-treat, M monthly, Q quarterly
Fig. 5 Mean percent change in pre-bronchodilator FEV1 from baseline.
FEV1 for each treatment arm was measured through Week 36. Error
bars represent the standard error of the mean. M, monthly; Q, quarterly
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identified patients with increased clinical benefit from leb-
rikizumab and omalizumab [10, 11], did not consistently
enrich for increased benefit from quilizumab in this study.
Similarly, patients with elevated serum IgE levels at base-
line did not respond better to quilizumab nor was there a
correlation between serum IgE reduction and exacerba-
tion reduction or FEV1 improvement (data not shown).
Conclusions
In adults with uncontrolled allergic asthma, a 36-week
treatment with quilizumab, an anti-M1-prime monoclo-
nal antibody that targets IgE-switched and IgE memory
B cells, did not result in a clinically significant impact on
exacerbation rate, lung function, or quality of life. Our
data on quilizumab activity indicate that there are major
pathological mechanisms that extend beyond the new,
local production of IgE in patients with inadequately
controlled allergic asthma.
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